You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
An integrated analysis involving prostate cancer patients from China highlighted frequent FOXA1 mutations and deletions in two other genes.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development.
The firm said current adoption is robust, but enabling readout on NGS instruments this summer will be crucial to opening a much larger customer base.
The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The Medicare Administrative Contractor will provide limited coverage for the RNA gene expression test that helps rule out primary cutaneous melanoma.
A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.
Undark looks into how coronavirus-related shutdowns are affecting field researchers.
In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.